FDA Approves HIV Test for Use with VITROS ECi/ECiQ Immunodiagnostic System


The 4th generation VITROS HIV Combo test has been approved for use with the VITROS ECi/ECiQ Immunodiagnostic System.


The US Food and Drug Administration (FDA) has approved the VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator (VITROS HIV Combo test) for use with Ortho Clinical Diagnostics’ VITROS ECi/ECiQ Immunodiagnostic System.

"Early detection of HIV-1 is critical in getting patients into treatment as soon as possible after infection," said Jennifer Paine, MS, Ortho Clinical Diagnostics' chief product portfolio and quality, regulatory and compliance officer, in a statement. "Ortho is proud to be working to deliver our VITROS HIV Combo test to customers worldwide."

The VITROS HIV Combo test is a 4th generation assay that detects both HIV-1 and HIV-2 antibodies as well as the p24 antigen. Detection of the p24 antigen, rather than just the antibodies to the antigen, allows the test to detect HIV-1 acute infection earlier than other generations of tests.

The VITROS HIV Combo test has been evaluated for clinical and technical performance at 3 external testing laboratories in the United States as well as at Ortho Clinical Diagnostics’ research and development laboratories.

Studies comparing the VITROS HIV Combo test to other 4th generation antigen or antibody tests showed earlier detection of acute HIV infection in 6 of 32 seroconversion panels and agreement for 25 of the 32 panels.

According to data in the VITROS HIV Combo Instructions for Use, the specificity of the VITROS HIV Combo test in the adults at low risk for HIV infection was 99.58% (95% confidence interval [CI], 99.38% to 99.73%). The sensitivity of the assay in samples from US HIV-positive subjects infected with HIV-2 was 100.00% (95% CI, 98.40% to 100.00%). The sensitivity for those positive for HIV-1 was 100.00% (95% CI, 99.62% to 100.00%).

The FDA has previously approved the use of the VIRTOS HIV Combo test with other Ortho Clinical Diagnostics systems, including the VITROS 5600 Integrated System earlier this year and the VITROS 3600 Immunodiagnostic System in December 2017.

"Ortho is committed to expanding its assay menu to meet current guidelines and testing needs," said Paine in a statement at the time of the test’s approval for use with the VITROS 5600 Integrated System. "With the availability of the VITROS HIV Combo test on the VITROS 5600 System, laboratories can improve workflow efficiencies while helping to provide earlier detection of HIV infection."

Related Videos
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Maternal Hidradenitits Suppurativa Linked to Neonatal Mortality, Pediatric Hospitalization Risk
Nanette B. Silverberg, MD: Uncovering Molluscum Epidemiology
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
A Year of RSV Highs and Lows, with Tina Tan, MD
Gestational Low-Dose Aspirin Does Not Increase Risk of IBD Flares in Women
Ryan A. Smith, MD: RSV Risk in Patients with IBD
Riha Bhatt, MD: Mimickers and Concurrent Diseases in Pediatric IBD
Elizabeth Spencer, MD: Precision Medicine in Pediatric IBD
Anita Clayton, MD: Zuranolone for Postpartum Depression
© 2024 MJH Life Sciences

All rights reserved.